532.79 Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Michele Flood Examiner #: 77454 Date: 10-19-2001
Art Unit: 1651 Phone Number 308-9432 Serial Number: 09/646,740
Mail Box and Bldg/Room Location: ~~Room~~ 1160 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Utilization of extracts from Iris Plants, Cimicifuga Racemosa and Tectiorigenin as an estrogen-like organ-selective medicament without uterotropic effects

Inventors (please provide full names): Wolfgang Wuttke; Hubertus Jarry; Walker Christoffel; Barbara Spengler; Michael Papp

Earliest Priority Filing Date: 3/19/1998

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Method for producing an estrogen type effect without uterotrophic effect comprising administering an Iridaceae extract, with the proviso that Belamcandra chinesis extract is not used to for treating peri-menopausal and post-menopausal disorders; extract comprises tectorigenin and tectorigenic glycoside used to treat/prevent cardiovascular disease, atherosclerosis, osteoporosis, climacteric disorders, prevention/alleviation of hot flashes"

"The claimed method wherein the extract is Belamcandra chinesis.

11-1-01

Claims Attached.

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Point of Contact: Alex Weclawiw	NA Sequence (#)_____	STN $
Searcher Phone #: Technical Info. Specialist	AA Sequence (#)_____	Dialog
Searcher Location: CM1 12C14 Tel: 308-4491	Structure (#) _____	Questel/Orbit
Date Searcher Picked Up: 10-29-01	Bibliographic ✓	Dr.Link
Date Completed: 11-14-01	Litigation _____	Lexis/Nexis
Searcher Prep & Review Time: 12	Fulltext _____	Sequence Systems
Clerical Prep Time: _____	Patent Family _____	WWW/Internet
Online Time: _____	Other _____	Other (specify)

PTO-1590 (1-2000)

```
=> d his

     (FILE 'REGISTRY' ENTERED AT 14:37:58 ON 29 OCT 2001)
               DEL HIS Y

     FILE 'HCAPLUS' ENTERED AT 14:39:03 ON 29 OCT 2001

     FILE 'STNGUIDE' ENTERED AT 14:39:27 ON 29 OCT 2001

     FILE 'REGISTRY' ENTERED AT 14:43:14 ON 29 OCT 2001
               E TECTORIGENIN/CN
L1             1 S E3
L2             1 S E4

     FILE 'HCAPLUS' ENTERED AT 14:44:01 ON 29 OCT 2001
L3            61 S L1 OR L2
L4             1 S TETORIGENIN?
L5            76 S TECTORIGENIN?
L6            86 S L3 OR L5
L7           394 S IRIDACEAE OR IRIS (L) PLANT#
L8             0 S BELAMCANDRA CHINESIS
L9             2 S BELAMCANDA CHINESIS
L10           55 S BELAMCANDA CHINENSIS
L11            0 S BELAMCANDRA CHINENSIS
L12          443 S L10 OR L7 OR L9
L13           40 S L12 (L) EXT?
L14         3301 S ANTIARTERIOSCLERO? OR ANTIARTHEROSCLER?
L15         5733 S CARDIOVASCULAR AGENT#
L16            1 S MENPAUSE
L17         6989 S OSTEOPOROSIS OR CLIMACTER?
L18         4846 S MENOPAUSE
L19            1 S L13 AND (L14-L18)
L20            1 S L6 AND (L14-L18)
L21            2 S L7 AND (L14-L18)
L22          101 S HOT FLASH? AND (L6 OR L14-L18)
L23            1 S HOT FLASH# AND (L6 OR L12)
L24            2 S L19 OR L20 OR L21 OR L23
L25        49162 S ESTROGEN?
L26            3 S L25 AND (L6 OR L12)
L27            4 S L24 OR  L26
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 14:53:27 ON 29 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   28 OCT 2001  HIGHEST RN 365210-66-8
DICTIONARY FILE UPDATES:  28 OCT 2001  HIGHEST RN 365210-66-8

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER see
HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d que l1;d l1
L1             1 SEA FILE=REGISTRY ABB=ON  TECTORIGENIN/CN
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 548-77-6 REGISTRY
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Isoflavone, 4',5,7-trihydroxy-6-methoxy- (7CI, 8CI)
CN **Tectorigenin (6CI)**
OTHER NAMES:
CN K 251T
FS 3D CONCORD
MF C16 H12 O6
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, NAPRALERT, RTECS*, TOXLIT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

59 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
59 REFERENCES IN FILE CAPLUS (1967 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> d que l2; d l2
L2             1 SEA FILE=REGISTRY ABB=ON  "TECTORIGENIN 4'-GLUCOSIDE"/CN


L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2001 ACS
RN   141894-63-5  REGISTRY
CN   4H-1-Benzopyran-4-one, 3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-5,7-
     dihydroxy-6-methoxy- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Tectorigenin 4'-glucoside
FS   STEREOSEARCH
MF   C22 H22 O11
SR   CA
LC   STN Files:   AGRICOLA, BEILSTEIN*, CA, CAPLUS
         (*File contains numerically searchable property data)

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              2 REFERENCES IN FILE CA (1967 TO DATE)
              2 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:53:48 ON 29 OCT 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1947 - 29 Oct 2001  VOL 135 ISS 19
FILE LAST UPDATED: 28 Oct 2001  (20011028/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REG1stRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

HCAplus now provides online access to patents and literature covered
in CA from 1947 to the present.  On April 22, 2001, bibliographic
```

information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his l3-

(FILE 'REGISTRY' ENTERED AT 14:43:14 ON 29 OCT 2001)

FILE 'HCAPLUS' ENTERED AT 14:44:01 ON 29 OCT 2001

```
L3          61 S L1 OR L2
L4           1 S TETORIGENIN?
L5          76 S TECTORIGENIN?
L6          86 S L3 OR L5
L7         394 S IRIDACEAE OR IRIS (L) PLANT#
L8           0 S BELAMCANDRA CHINESIS
L9           2 S BELAMCANDA CHINESIS
L10         55 S BELAMCANDA CHINENSIS
L11          0 S BELAMCANDRA CHINENSIS
L12        443 S L10 OR L7 OR L9
L13         40 S L12 (L) EXT?
L14       3301 S ANTIARTERIOSCLERO? OR ANTIARTHEROSCLER?
L15       5733 S CARDIOVASCULAR AGENT#
L16          1 S MENPAUSE
L17       6989 S OSTEOPOROSIS OR CLIMACTER?
L18       4846 S MENOPAUSE
L19          1 S L13 AND (L14-L18)
L20          1 S L6 AND (L14-L18)
L21          2 S L7 AND (L14-L18)
L22        101 S HOT FLASH? AND (L6 OR L14-L18)
L23          1 S HOT FLASH# AND (L6 OR L12)
L24          2 S L19 OR L20 OR L21 OR L23
L25      49162 S ESTROGEN?
L26          3 S L25 AND (L6 OR L12)
L27          4 S L24 OR  L26
```

FILE 'REGISTRY' ENTERED AT 14:53:27 ON 29 OCT 2001

FILE 'HCAPLUS' ENTERED AT 14:53:48 ON 29 OCT 2001

=> d .ca l27 1-4

L27 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:761931 HCAPLUS
DOCUMENT NUMBER: 133:325492
TITLE: Breast-enlarging agent containing Pueraria root products
INVENTOR(S): Hirose, Katsutoshi; Katayama, Masato; Hirata, Naonori
PATENT ASSIGNEE(S): Kobe Tennenbutsu Kagaku K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000302667	A2	20001031	JP 1999-115773	19990423

AB The invention relates to a breast-enlarging agent contg. Pueraria root or its product, esp. Pueraria lobata or Pueraria thomsonii, contg. isoflavones. A powder of Puerariae Radix root was combined with vaseline to obtain an ointment. The agent may further use for treatment and

prevention of menopausal syndrome, skin-whitening, or hair growth-stimulation.
IC ICM A61K007-48
ICS A61K007-00; A61K007-06; A61P017-00; A61P017-14; A61P043-00; A61K031-352; A61K035-78
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
IT **Menopause**
(Pueraria root products for menopausal syndrome treatment)
IT **Iridaceae**
Kudzu (Pueraria)
Kudzu (Pueraria lobata)
Kudzu (Pueraria thomsoni)
Mammary gland
(breast-enlarging agent contg. Pueraria root products)

L27 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:67487 HCAPLUS
DOCUMENT NUMBER: 132:97858
TITLE: Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
INVENTOR(S): Segelman, Alvin B.
PATENT ASSIGNEE(S): Natures Sunshine Products, Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6017893	A	20000125	US 1997-920955	19970829

PRIORITY APPLN. INFO.: US 1996-25810 19960830
OTHER SOURCE(S): MARPAT 132:97858
AB The present invention is an orally- or topically-administrable compn. for preventing and treating hair loss. The invention is a plant or plant ext. contg. isoflavones having a weak estrogen activity. The invention further includes methods for using the invented compn. to prevent and treat hair loss. A hair lotion contained concd. semi-purified soybean exts. (contg. 20-50 % isoflavones), progesterone (up to 5 mg/30 mL), and a lotion base.
IC ICM A61K031-70
NCL 514027000
CC 62-3 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
IT **Estrogens**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. agent; isoflavones for prevention of hair loss)
IT **Iridaceae**
Legume (Fabaceae)
Marantaceae
Moraceae
Podocarpaceae
Rosaceae
Soybean (Glycine max)
(exts.; isoflavones for prevention of hair loss)
REFERENCE COUNT: 7
REFERENCE(S): (1) Anon; JP 05-78347 1993 HCAPLUS
(2) Anon; WO 96/10387 1996 HCAPLUS
(3) Delgado; 1996 HCAPLUS
(4) Hakamata; 1993 HCAPLUS
(5) Kung; US 5639715 1997 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:613676 HCAPLUS
DOCUMENT NUMBER: 131:223505
TITLE: Utilization of **extracts** from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects
INVENTOR(S): Wuttke, Wolfgang; Jarry, Hubertus; Christoffel, Volker; Spengler, Barbara; Popp, Michael
PATENT ASSIGNEE(S): Plantamed Arzneimittel G.m.b.H., Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947149	A1	19990923	WO 1999-EP1860	19990319
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9931466	A1	19991011	AU 1999-31466	19990319
BR 9908256	A	20001212	BR 1999-8256	19990319
EP 1064009	A1	20010103	EP 1999-913282	19990319
R: AT, CH, DE, DK, ES, FR, GB, GR, IT, LI, SE, PT				

PRIORITY APPLN. INFO.: DE 1998-19812204 A 19980319
WO 1999-EP1860 W 19990319

AB Exts. from iris plants [esp. Belamcanda sinensis (Iridaceae)], exts. from C. racemosa, and tectorigenin and tectorigenin glycosides obtained from B. sinensis are useful as estrogenlike organ-selective medicaments for selective treatment and/or prophylaxis of cardiovascular diseases (esp. arteriolosclerosis), osteoporosis, and climacteric symptoms (e.g. hot flashes). Virtually no uterotropic effects are obsd. when using these medicaments. Thus, lipophilic components of C. racemosa exts. bound strongly to anti-estradiol antibodies and to cytosolic estradiol receptors from pig uterus. Administration of B. sinensis ext. i.v. inhibited the pulsatile release of gonadotropin-releasing hormone in ovariectomized rats and inhibited LH secretion, without affecting the expression of uterine genes for VEGF, IGF-1, and C3.

IC ICM A61K035-78
ICS A61K031-35
CC 1-8 (Pharmacology)
Section cross-reference(s): 2, 63
ST **estrogen iris** Cimicifuga Belamcanda; cardiovascular disease **estrogen plant ext;**
osteoporosis estrogen plant ext;
climacteric estrogen plant ext;
tectorigenin cardiovascular disease **osteoporosis climacteric**
IT **Antiarteriosclerotics**
(antiatherosclerotics; utilization of **exts.** from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as

estrogenlike organ-selective medicaments without uterotropic effects)

IT **Menopause**
(disorder, **hot flash**; utilization of **exts** . from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects)

IT **Menopause**
(disorder; utilization of **exts**. from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects)

IT **Osteoporosis**
(therapeutic agents; utilization of **exts**. from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects)

IT **Belamcanda chinensis**
Cardiovascular agents
Cimicifuga racemosa
Iridaceae
(utilization of **exts**. from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects)

IT **Estrogens**
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(utilization of **exts**. from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects)

IT **548-77-6, Tectorigenin 548-77-6D, Tectorigenin**, glycosides
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(utilization of **exts**. from **iris plants**, Cimicifuga racemosa, and **tectorigenin** as **estrogenlike** organ-selective medicaments without uterotropic effects)

REFERENCE COUNT: 3
REFERENCE(S):
(1) Anon; EP 0847755 A
(2) Schaper & Bruemmer GMBH; DE 19652183 C 1998 HCAPLUS
(3) Tsumura Juntendo Inc; JP 63030417 A 1988 HCAPLUS

L27 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:599509 HCAPLUS
DOCUMENT NUMBER: 132:132284
TITLE: Phytochemical and pharmacological studies of Dalbergia sissoo growing in Egypt
AUTHOR(S): Sarg, Taha; Ateya, Abdel-Monem; Abdel-Ghani, Afaf; Badr, Wafaa; Shams, Gamal
CORPORATE SOURCE: Department of Pharmacognosy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
SOURCE: Pharm. Biol. (Lisse, Neth.) (1999), 37(1), 54-62
CODEN: PHBIFC; ISSN: 1388-0209
PUBLISHER: Swets & Zeitlinger B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The isoflavones irisolidone, biochanin-A, muningin, tectorigenin, prunetin, genistein, sissotrin and prunetin-4-O-galactoside, the flavone norartocarpetin, and .beta.-amyrin, .beta.-sitosterol and stigmasterol were isolated and identified from the green branches of aerial parts of Dalbergia sissoo Roxb, using silica gel column chromatog. and spectral

anal. Also, 13 fatty acids were identified. The alc. ext. of the green branches of aerial parts showed a dose-dependent inhibitory effect on the motility of isolated rabbit duodenum, pronounced bronchodilation, as well as significant anti-inflammatory, antipyretic, analgesic, and estrogen-like activities. The plant ext. was well-tolerated by rats.

CC 1-12 (Pharmacology)
Section cross-reference(s): 11

IT **Estrogens**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(-like activity; phytochem. and pharmacol. studies of Dalbergia sissoo growing in Egypt)

IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Stearic acid, biological studies 60-33-3, Linoleic acid, biological studies 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 112-80-1, cis-9-Octadecenoic acid, biological studies 124-07-2, Octanoic acid, biological studies 143-07-7, Dodecanoic acid, biological studies 373-49-9, Palmitoleic acid 446-72-0, Genistein 479-83-4, Muningin 491-80-5, Biochanin-A 506-12-7, Heptadecanoic acid 506-26-3, .gamma.-Linolenic acid 520-30-9, Norartocarpetin 544-63-8, Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid **548-77-6**, **Tectorigenin** 552-59-0, Prunetin 559-70-6, .beta.-Amyrin 638-53-9, Tridecanoic acid 1002-84-2, Pentadecanoic acid 2345-17-7, Irisolidone 5928-26-7, Sissotrin 117007-27-9
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(phytochem. and pharmacol. studies of Dalbergia sissoo growing in Egypt)

REFERENCE COUNT: 32

REFERENCE(S):

(1) Ahluwalia, V; Indian J Chem 1965, V3, P474 HCAPLUS
(6) Campbell, R; J Chem Soc (C) 1969, P1787 HCAPLUS
(12) Goda, Y; Chem Pharm Bull 1985, V33, P5606 HCAPLUS
(17) King, F; J Chem Soc 1952, P96 HCAPLUS
(23) Mukerjee, S; Tetrahedron 1971, V27, P799 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil wpids

FILE 'WPIDS' ENTERED AT 15:04:27 ON 29 OCT 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE LAST UPDATED: 26 OCT 2001              <20011026/UP>
MOST RECENT DERWENT UPDATE            200162   <200162/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> Due to data production difficulties the latest DCR data
    loaded is for update 200160 <<<

>>> SDI'S MAY BE RUN ON EVERY UPDATE OR MONTHLY AS OF JUNE 2001.
    (EVERY UPDATE IS THE DEFAULT). FOR PRICING INFORMATION
    SEE HELP COST <<<

>>> FOR UP-TO-DATE INFORMATION ABOUT THE DERWENT CHEMISTRY
    RESOURCE, PLEASE VISIT
         http://www.derwent.com/chemistryresource/index.html <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
    SEE http://www.derwent.com/covcodes.html  <<<

=> d his

     (FILE 'WPIDS' ENTERED AT 14:56:40 ON 29 OCT 2001)
                DEL HIS Y
L1             0 S (BELAMCANDRA OR BELEMANDA)(W) CHINENIS
L2             0 S (BELAMCANDRA OR BELEMANDA)(W) CHINENSIS
L3           111 S IRIDACEAE OR IRIS (L) PLANT#
L4             5 S TECTORIGENIN?
L5           115 S L3 OR L4
L6            26 S L5 AND B04/DC
L7          6083 S ?ARTERIOSCLERO? OR ?ARTHEROSCLER?
L8           357 S MENOPAUSE OR OSTEROPOROSIS OR HOT FLASH?
L9             1 S L6 AND (L7 OR L8)
L10          183 S CLIMACTER?
L11            1 S L6 AND L10
L12         9450 S CARDIOVAS?
L13            3 S L12 AND L5
L14            4 S L13 OR L11 OR L9
L15           22 S L6 NOT L14

     FILE 'WPIDS' ENTERED AT 15:04:27 ON 29 OCT 2001

=> d .wp l14 1-4;d bib l15 1-22

L14  ANSWER 1 OF 4  WPIDS COPYRIGHT 2001   DERWENT INFORMATION LTD
AN   2001-151164 [16]   WPIDS
DNC  C2001-045110
TI   Breast promoter useful as therapeutic agent for preventing
     menopause and improving skin whitening and hair restoration in
     humans, contains processed roots or other parts of arrow root as active
     ingredient.
DC   B04 D21
PA   (KOBE-N) KOBE TENNENBUTSU KAGAKU KK
CYC  1
PI   JP 2000302667 A  20001031 (200116)*       9p
ADT  JP 2000302667 A JP 1999-115773 19990423
PRAI JP 1999-115773   19990423
AB   JP2000302667 A UPAB: 20010323
     NOVELTY - A breast promoter contains processed roots or other parts of
```

arrow root as active ingredient.
ACTIVITY - Antipyratic; antiplasmodic; hypertensive; antidiarrheic. No test details are given in the specification.
MECHANISM OF ACTION - None given.
USE - Useful as therapeutic agent for preventing **menopause** and for improving skin whitening and hair restoration in humans (claimed).
ADVANTAGE - The promoter effectively promotes skin whitening, breast development, prevents **menopause** and restores hair growth. The proliferation of mammary gland cells was tested in wister female rats by administering the liquid formulation containing arrow root for 1 week at an interval of 6 hours. The rats at the end of 50 days showed 10.2 vol/vol % increase and at the end of 80 days showed 15.1 vol/vol % increase in the proliferation of mammary cells.
Dwg.0/0

L14 ANSWER 2 OF 4 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1999-561850 [47] WPIDS
DNC C1999-163781
TI Selective estrogenic **plant** extracts, e.g. from **iris plants** or containing **tectorigenin**, useful e.g. for treating atherosclerosis or osteoporosis.
DC **B04**
IN CHRISTOFFEL, V; JARRY, H; POPP, M; SPENGLER, B; WUTTKE, W
PA (PLAN-N) PLANTAMED ARZNEIMITTEL GMBH
CYC 87
PI WO 9947149 A1 19990923 (199947)* DE 27p
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW
DE 19812204 A1 19991104 (199953)
AU 9931466 A 19991011 (200008)
BR 9908256 A 20001212 (200102)
EP 1064009 A1 20010103 (200102) DE
R: AT CH DE DK ES FR GB GR IT LI PT SE
CZ 2000002810 A3 20001213 (200103)
CN 1293575 A 20010502 (200143)
ADT WO 9947149 A1 WO 1999-EP1860 19990319; DE 19812204 A1 DE 1998-19812204 19980319; AU 9931466 A AU 1999-31466 19990319; BR 9908256 A BR 1999-8256 19990319, WO 1999-EP1860 19990319; EP 1064009 A1 EP 1999-913282 19990319, WO 1999-EP1860 19990319; CZ 2000002810 A3 WO 1999-EP1860 19990319, CZ 2000-2810 19990319; CN 1293575 A CN 1999-804123 19990319
FDT AU 9931466 A Based on WO 9947149; BR 9908256 A Based on WO 9947149; EP 1064009 A1 Based on WO 9947149; CZ 2000002810 A3 Based on WO 9947149
PRAI DE 1998-19812204 19980319
AB WO 9947149 A UPAB: 19991116
NOVELTY - Organ-selective estrogenic medicaments comprise extracts of **iris plants**, extracts of Cimifuga racemosa or extracts containing (or enriched in) **tectorigenin** (TG) and/or TG glycoside.
DETAILED DESCRIPTION - The use of the following is claimed for the production of organ-selective estrogenic medicaments having no (or negligible) uterotropic activity:
(i) extracts of **iris plants** (**Iridaceae**), specifically extracts of Belamcanda sinensis;
(ii) extracts of Cimifuga racemosa; or
(iii) extracts containing (or enriched in) TG of formula (I) and/or TG glycoside:
INDEPENDENT CLAIMS are included for the following:
(1) TG and/or its glycoside as a medicament; and
(2) **plant** extracts containing (or enriched in) TG and/or

its glycoside.

ACTIVITY - **Cardiovascular**; bone resorption inhibiting; **climacteric**.

MECHANISM OF ACTION - Selective estrogen receptor agonist. Ovariectomized rats were injected subcutaneously once daily with 62.5 mg of Cimicifuga racemosa extract (CR) or 8 micro g of estradiol (E2) for 7 days, using 5% Cremophor (RTM) as vehicle. Expression of mRNA for E2 receptor alpha in the preoptic region of the hypothalamus was approximately doubled (relative to vehicle-only treated controls) in both the CR and E2 treated groups.

USE - Organ-selective estrogenic medicaments are useful for the selective treatment and/or prophylaxis of **cardiovascular** disease (especially atherosclerosis), osteoporosis or **climacteric** disorders (especially for inhibiting or alleviating hot flushes) (all claimed).

ADVANTAGE - The extracts have beneficial estrogenic effects on the brain, ovaries, bones and vascular system, but no harmful side-effects on the uterus, vagina, breast tissue and liver.

Dwg.0/3

L14 ANSWER 3 OF 4 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1997-201883 [18] WPIDS
DNC C1997-064503
TI Cell extracts from plant of **Iridaceae** family - used in compsns. for treating CNS, respiratory, skin, **cardiovascular**, immunological and urinary tract disorders.
DC B04 B05 D21
IN BRETON, L; DE, LACHARRIERE O; MARTIN, R
PA (OREA) L'OREAL SA
CYC 12
PI WO 9709056 A1 19970313 (199718)* FR 55p
W: BR MX PL RU
EP 765668 A1 19970402 (199718) FR 27p
R: DE ES FR GB IT SE
FR 2738486 A1 19970314 (199720) 20p
FR 2738488 A1 19970314 (199720) 23p
CA 2185037 A 19970308 (199728) FR
JP 09124499 A 19970513 (199729) 22p
FR 2746647 A1 19971003 (199747) 33p
EP 765668 B1 19990317 (199915) FR
R: DE ES FR GB IT SE
DE 69601765 E 19990422 (199922)
BR 9610375 A 19990706 (199938)
ES 2132855 T3 19990816 (199939)
MX 9710479 A1 19980301 (200002)
JP 3093154 B2 20001003 (200051) 21p
RU 2169000 C2 20010620 (200144)
ADT WO 9709056 A1 WO 1996-FR1285 19960813; EP 765668 A1 EP 1996-401782 19960813; FR 2738486 A1 FR 1995-10486 19950907; FR 2738488 A1 FR 1995-10487 19950907; CA 2185037 A CA 1996-2185037 19960906; JP 09124499 A JP 1996-236986 19960906; FR 2746647 A1 FR 1996-3815 19960327; EP 765668 B1 EP 1996-401782 19960813; DE 69601765 E DE 1996-601765 19960813, EP 1996-401782 19960813; BR 9610375 A BR 1996-10375 19960813, WO 1996-FR1285 19960813; ES 2132855 T3 EP 1996-401782 19960813; MX 9710479 A1 MX 1997-10479 19971219; JP 3093154 B2 JP 1996-236986 19960906; RU 2169000 C2 WO 1996-FR1285 19960813, RU 1997-121856 19960813
FDT DE 69601765 E Based on EP 765668; BR 9610375 A Based on WO 9709056; ES 2132855 T3 Based on EP 765668; JP 3093154 B2 Previous Publ. JP 09124499; RU 2169000 C2 Based on WO 9709056
PRAI FR 1996-3815 19960327; FR 1995-10486 19950907; FR 1995-10487 19950907
AB WO 9709056 A UPAB: 19970502
Extract of cells (I) of at least 1 plant of the **Iridaceae**

family, obtd. by in vitro culture, is new.
Also claimed are compsns. comprising:(1) (I) and at least 1 prod. having an irritant effect, or(2) (I) and a cpd. which reduces the synthesis, liberation and/or activity of at least 1 inflammation mediator excluding steroidal and non-steroidal antiinflammatory agents.

USE - The extract is used in cosmetic or pharmaceutical compsns. for treating CNS disorders, respiratory disorders, allergic syndromes, inflammation, pain, gastrointestinal disorders, skin disorders, fibroses, collagen maturation disorders, **cardiovascular** disorders, vasospastic disorders, immunological disorders and/or urinary tract disorders. The compsns. are used for treating sensitive skins, e.g. for treating and/or preventing skin irritation, erythemas, sores, pain, inflammation and pruritus of the skin or mucous membranes. (I) can also be used as a CGRP and/or substance P antagonist and to treat disorders associated with an excess of the synthesis and/or liberation of CGRP and/or substance P. The compsns. are used for topical cosmetic treatment of the skin, hair and/or mucous membranes (all claimed).
Dwg.0/0

L14 ANSWER 4 OF 4 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1997-156643 [15] WPIDS
DNC C1997-050232
TI Use of extracts of non-photosynthetic filamentous bacteria as substance P antagonists - in cosmetic and pharmaceutical compsns..
DC B04 D16 D21
IN AUBERT, L; BRETON, L; DE, LACHARRIERE O; LECLAIRE, J; MARTIN, R
PA (OREA) L'OREAL SA; (OREA) SOC L'OREAL SA
CYC 13
PI EP 761204 A1 19970312 (199715)* FR 32p
R: DE ES FR GB IT SE
WO 9709032 A1 19970313 (199717) FR 61p
W: BR JP MX PL RU
FR 2738485 A1 19970314 (199720) 29p
CA 2185036 A 19970308 (199728) FR
FR 2746642 A1 19971003 (199747) 33p
FR 2746646 A1 19971003 (199747) 21p
EP 761204 B1 19980415 (199819) FR 44p
R: DE ES FR GB IT SE
DE 69600242 E 19980520 (199826)
US 5795574 A 19980818 (199840)
ES 2120274 T3 19981016 (199849)
JP 10511110 W 19981027 (199902) 69p
BR 9608500 A 19990706 (199938)
MX 9710478 A1 19980801 (200014)
ADT EP 761204 A1 EP 1996-401781 19960813; WO 9709032 A1 WO 1996-FR1284 19960813; FR 2738485 A1 FR 1995-10485 19950907; CA 2185036 A CA 1996-2185036 19960906; FR 2746642 A1 FR 1996-3818 19960327; FR 2746646 A1 FR 1996-3816 19960327; EP 761204 B1 EP 1996-401781 19960813; DE 69600242 E DE 1996-600242 19960813, EP 1996-401781 19960813; US 5795574 A US 1996-711109 19960909; ES 2120274 T3 EP 1996-401781 19960813; JP 10511110 W WO 1996-FR1284 19960813, JP 1997-510896 19960813; BR 9608500 A BR 1996-8500 19960813, WO 1996-FR1284 19960813; MX 9710478 A1 MX 1997-10478 19971219
FDT DE 69600242 E Based on EP 761204; ES 2120274 T3 Based on EP 761204; JP 10511110 W Based on WO 9709032; BR 9608500 A Based on WO 9709032
PRAI FR 1996-3818 19960327; FR 1995-10485 19950907; FR 1996-3816 19960327
AB EP 761204 A UPAB: 19970410
The following are claimed: (1) use of extracts (I) of non-photosynthetic filamentous bacteria as substance P antagonists in cosmetic compsns. or for prepn. of pharmaceutical compsns.; (2) cosmetic or pharmaceutical compsns. contg. (I) and prods. (II) with an irritant effect; (3) cosmetic or pharmaceutical compsns. contg. (I) and cell extracts (III) of plants of

the **Iridaceae** family; and (4) cosmetic or pharmaceutical compsns. contg. (I) and cpds. (IV) that reduce the synthesis, release and/or activity of inflammation mediators other than steroidal and nonsteroidal antiinflammatory agents.

USE - The compositions are useful for treating disorders associated with overproduction or excessive secretion of substance P, such as CNS disorders, respiratory disorders, allergies, inflammation, pain, gastrointestinal disorders, skin disorders, fibrosis, collagen maturation disorders, **cardiovascular** disorders, vasospasm, immunological disorders and/or disorders of the urinary tract; for treating sensitive skin; for preventing and/or combating skin and/or mucosal irritation (all claimed).

Dwg.0/0

L15 ANSWER 1 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2001-453935 [49] WPIDS
DNC C2001-137344
TI Peroxidation oxygen elimination agent for use as cosmetics, comprises essence obtained from specific plants of Rubiaceae, **Iridaceae**, Guttiferae, Compositae, Moraceae, Labiatae, and Zingiberaceae.
DC **B04** D21
PA (POKK) POLA CHEM IND INC
CYC 1
PI JP 2001131046 A 20010515 (200149)* 7p
ADT JP 2001131046 A JP 1999-313739 19991104
PRAI JP 1999-313739 19991104

L15 ANSWER 2 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2001-387141 [41] WPIDS
DNC C2001-118104
TI Protease inhibitor for improving and treating rough skin and other dermatological disorders such as keratonosis, comprises a plant extract of Pistacia, Lindera and/or Sapium.
DC **B04** D21
PA (SHIS) SHISEIDO CO LTD
CYC 1
PI JP 2001122728 A 20010508 (200141)* 9p
ADT JP 2001122728 A JP 1999-298557 19991020
PRAI JP 1999-298557 19991020

L15 ANSWER 3 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2001-285640 [30] WPIDS
DNC C2001-087500
TI Skin external preparation for use as anti-aging cosmetics, comprises natural extract containing trehalose and oily substance, and has moisturizing effect.
DC **B04** D21
PA (KAOS) KAO CORP
CYC 1
PI JP 2001039848 A 20010213 (200130)* 9p
ADT JP 2001039848 A JP 1999-212020 19990727
PRAI JP 1999-212020 19990727

L15 ANSWER 4 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2001-194007 [20] WPIDS
DNC C2001-058530
TI Serine protease inhibitor as skin external preparation and for treating dermatological disorders, comprises plants belonging to Rosaceae as the active ingredient.
DC **B04** D21

PA (SHIS) SHISEIDO CO LTD
CYC 1
PI JP 2000327555 A 20001128 (200120)* 9p
ADT JP 2000327555 A JP 1999-141358 19990521
PRAI JP 1999-141358 19990521

L15 ANSWER 5 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2001-051782 [07] WPIDS
DNC C2001-014396
TI External skin care composition comprises ceramide production-accelerating agent and film-forming polymer and enhances barrier function of skin and has excellent skin roughness-improving effect.
DC A96 B03 **B04** D21
IN HORI, K; OHASHI, Y; SANO, T; TAKAGI, Y; YAMAKI, K
PA (KAOS) KAO CORP
CYC 26
PI EP 1051965 A2 20001115 (200107)* EN 17p
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
JP 2000319157 A 20001121 (200108) 7p
ADT EP 1051965 A2 EP 2000-109171 20000508; JP 2000319157 A JP 1999-128255 19990510
PRAI JP 1999-128255 19990510

L15 ANSWER 6 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2000-194093 [17] WPIDS
DNC C2000-060070
TI Method of preparing a complex showing antiinflammatory, immunomodulating and antihypoxic effect.
DC **B04**
IN ASTAKHOVA, T V; MININA, S A; PRYAKHINA, N I
PA (SPET-R) ST PETERSBURG CHEM PHARM ACAD
CYC 1
PI RU 2123349 C1 19981220 (200017)*
ADT RU 2123349 C1 RU 1997-106405 19970418
PRAI RU 1997-106405 19970418

L15 ANSWER 7 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2000-137527 [13] WPIDS
DNC C2000-042325
TI Cosmetic and dermatological compositions made from plant materials, especially a synergistic mixture of liposoluble vegetable oils and liposoluble plant extracts.
DC **B04** D21
PA (RAQU-I) RAQUET J
CYC 1
PI BE 1011858 A7 20000201 (200013)* 49p
ADT BE 1011858 A7 BE 1998-249 19980401
PRAI BE 1998-249 19980401

L15 ANSWER 8 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2000-092575 [08] WPIDS
DNC C2000-026898
TI Agent and cosmetics for inhibiting production of melanin.
DC **B04** D21
PA (ICHP) ICHIMARU PHARCOS INC
CYC 1
PI JP 11335233 A 19991207 (200008)* 17p
ADT JP 11335233 A JP 1998-158542 19980522
PRAI JP 1998-158542 19980522

L15 ANSWER 9 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-581147 [49] WPIDS

DNC C1998-173691
TI After-shave cream composition having e.g. anti-inflammatory effect - comprises stearin, lanolin, glycerol, vegetable oil and ethanol, with yarrow, nettle, calendula, willowbark, burnet and bird cherry extracts.
DC **B04** D21
IN DOLOTOVSKAYA, L Z; DOLOTOVSKII, I M; SHMELEV, A YA
PA (UFCO-R) UFA COSMETICS WKS
CYC 1
PI RU 2109506 C1 19980427 (199849)* 6p
ADT RU 2109506 C1 RU 1995-105123 19950405
PRAI RU 1995-105123 19950405

L15 ANSWER 10 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-469739 [41] WPIDS
DNC C1998-142439
TI De-pigmenting compositions for skin etc. - contains phenol and **Iridaceae** extract.
DC **B04** B05 D21
IN BRETON, L
PA (OREA) L'OREAL SA
CYC 70
PI FR 2760191 A1 19980904 (199841)* 19p
WO 9838978 A1 19980911 (199842) FR
RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA US UZ VN YU ZW
AU 9867360 A 19980922 (199908)
EP 1019017 A1 20000719 (200036) FR
R: DE ES FR GB IT
CN 1253495 A 20000517 (200041)
JP 2000510165 W 20000808 (200043) 20p
KR 2000075870 A 20001226 (200134)
ADT FR 2760191 A1 FR 1997-2504 19970303; WO 9838978 A1 WO 1998-FR402 19980302; AU 9867360 A AU 1998-67360 19980302; EP 1019017 A1 EP 1998-912574 19980302, WO 1998-FR402 19980302; CN 1253495 A CN 1998-804617 19980302; JP 2000510165 W JP 1998-538224 19980302, WO 1998-FR402 19980302; KR 2000075870 A WO 1998-FR402 19980302, KR 1999-707949 19990901
FDT AU 9867360 A Based on WO 9838978; EP 1019017 A1 Based on WO 9838978; JP 2000510165 W Based on WO 9838978; KR 2000075870 A Based on WO 9838978
PRAI FR 1997-2504 19970303

L15 ANSWER 11 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-393405 [34] WPIDS
DNC C1998-119258
TI Antiinflammatory analgesic plaster for treating arthritis, etc. - comprises indomethacin and extracted substances and extract compositions of rhizoma of Iris germanica Lam., I. florentia L. and I. pallida L. (**Iridaceae**).
DC B02 **B04** B07
PA (TAIS) TAISHO PHARM CO LTD
CYC 1
PI JP 10158186 A 19980616 (199834)* 4p
ADT JP 10158186 A JP 1996-319144 19961129
PRAI JP 1996-319144 19961129

L15 ANSWER 12 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-090031 [09] WPIDS
DNN N1998-071373 DNC C1998-030496
TI New lectin produced by expression of plant of **Iridaceae** - used in separation or purification of polysaccharide(s) or glyco-protein(s) or as antiviral agent or growth inhibitor against fungi, etc..
DC **B04** C03 S03

PA (TKAK) TAYCA CORP
CYC 1
PI JP 09124694 A 19970513 (199809)* 7p
ADT JP 09124694 A JP 1995-305028 19951030
PRAI JP 1995-305028 19951030

L15 ANSWER 13 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-059103 [06] WPIDS
DNC C1998-020387
TI Belamcanda chinensis L. extracts, cell activating agent contg. alpha-hydroxy acid, and their usage - used for bathing compositions or skin external compositions.
DC **B04** D21
PA (ICHP) ICHIMARU PHARCOS INC
CYC 1
PI JP 09301883 A 19971125 (199806)* 13p
ADT JP 09301883 A JP 1996-146822 19960515
PRAI JP 1996-146822 19960515

L15 ANSWER 14 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1997-460242 [43] WPIDS
DNC C1997-147046
TI Skin or hair treatment composition - contains undifferentiated Ginkgo biloba cells or their extracts, and is free of irritant and/or allergenic components.
DC **B04** D21
IN MARTIN, R; MELLUL, M
PA (OREA) L'OREAL SA
CYC 1
PI FR 2744915 A1 19970822 (199743)* 24p
ADT FR 2744915 A1 FR 1996-1969 19960216
PRAI FR 1996-1969 19960216

L15 ANSWER 15 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1997-161403 [15] WPIDS
DNC C1997-051681
TI An external compsn for fair skin for e g sunburn treatment - comprises solvent extract of **Iridaceae** family.
DC **B04** D21
PA (SHIS) SHISEIDO CO LTD
CYC 1
PI JP 09030954 A 19970204 (199715)* 10p
ADT JP 09030954 A JP 1996-84750 19960313
PRAI JP 1995-142680 19950517

L15 ANSWER 16 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1995-228635 [30] WPIDS
DNC C1995-105333
TI Testosterone 5-alpha reductase inhibitor contg. extract of Belamcanda chinensis L. - is used in prepns. for treatment of seborrhea, acne vulgaris and male alopecia.
DC **B04** D16 D21
PA (ICHP) ICHIMARU PHARCOS INC
CYC 1
PI JP 07138181 A 19950530 (199530)* 6p
ADT JP 07138181 A JP 1993-309859 19931115
PRAI JP 1993-309859 19931115

L15 ANSWER 17 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1995-228633 [30] WPIDS
DNC C1995-105331
TI Cell activator for preventing skin ageing - comprises Belamcanda chinensis L., belonging to **Iridaceae** or its dried roots extracts with e.g.

water.
DC **B04** D21
PA (ICHP) ICHIMARU PHARCOS INC
CYC 1
PI JP 07138179 A 19950530 (199530)* 7p
ADT JP 07138179 A JP 1993-309858 19931115
PRAI JP 1993-309858 19931115

L15 ANSWER 18 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1989-008908 [02] WPIDS
DNC C1989-004122
TI Herbal compsn. for treating skin and scalp disorders - e.g. psoriasis and hair loss, is infusion of lavender, mint, sage, etc. in vinegar.
DC **B04** D21
IN PASINI, I
PA (IRIS-N) IRIS SAS DI SALVIOL
CYC 14
PI EP 297640 A 19890104 (198902)* EN 5p
R: AT BE CH DE ES FR GB GR LI LU NL SE
US 4855131 A 19890808 (198939) 3p
IT 1206794 B 19890503 (199131)
EP 297640 B 19910828 (199135)
R: AT BE CH DE ES FR GB GR LI LU NL SE
DE 3864464 G 19911002 (199141)
ADT EP 297640 A EP 1988-201129 19880604; US 4855131 A US 1988-203910 19880608
PRAI IT 1987-21115 19870630

L15 ANSWER 19 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1988-296436 [42] WPIDS
DNC C1988-131535
TI Agent for treatment of peptic ulcers - contains alcohol-soluble fraction of ether-insol. fraction of alcohol extract of Iris root.
DC **B04**
PA (ZERI) ZERIA SHINYAKU KOGYO KK
CYC 1
PI JP 63216824 A 19880909 (198842)* 6p
ADT JP 63216824 A JP 1987-50495 19870305
PRAI JP 1987-50495 19870305

L15 ANSWER 20 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1988-268231 [38] WPIDS
DNC C1988-119536
TI Anti-peptic ulcer drug - is extracted from roots of iris using alcohol and further extracted using ether, giving solubility in tri chloro-methane etc..
DC **B04**
PA (ZERI) ZERIA SHINYAKU KOGYO KK
CYC 1
PI JP 63196522 A 19880815 (198838)* 7p
ADT JP 63196522 A JP 1987-29237 19870210
PRAI JP 1987-29237 19870210

L15 ANSWER 21 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1985-248004 [40] WPIDS
DNC C1985-107742
TI Embinin prepn. by extn. and column chromatography - involves using over-ground part of iris as raw material and alkaline treatment.
DC **B04** D16
IN BLINOVA, K F; GLYZIN, V I; PRYAKHINA, N I
PA (LECH-R) LENGD CHEM PHARM
CYC 1
PI SU 1146049 A 19850323 (198540)* 2p
ADT SU 1146049 A SU 1983-3549586 19830207

PRAI SU 1983-3549586 19830207

L15 ANSWER 22 OF 22 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1985-070439 [12] WPIDS
DNC C1985-030444
TI Anticancer flower of cancer - used to treat cancer of digestive organs.
DC **B04**
PA (WANA-I) WATANABE K
CYC 1
PI JP 57007422 A 19820114 (198512)* 3p
ADT JP 57007422 A JP 1980-81111 19800614
PRAI JP 1980-81111 19800614

```
=> d his

     (FILE 'WPIDS' ENTERED AT 14:56:40 ON 29 OCT 2001)
                DEL HIS Y
L1            0 S (BELAMCANDRA OR BELEMANDA)(W) CHINENIS
L2            0 S (BELAMCANDRA OR BELEMANDA)(W) CHINENSIS
L3          111 S IRIDACEAE OR IRIS (L) PLANT#
L4            5 S TECTORIGENIN?
L5          115 S L3 OR L4
L6           26 S L5 AND B04/DC
L7         6083 S ?ARTERIOSCLERO? OR ?ARTHEROSCLER?
L8          357 S MENOPAUSE OR OSTEROPOROSIS OR HOT FLASH?
L9            1 S L6 AND (L7 OR L8)
L10         183 S CLIMACTER?
L11           1 S L6 AND L10
L12        9450 S CARDIOVAS?
L13           3 S L12 AND L5
L14           4 S L13 OR L11 OR L9
L15          22 S L6 NOT L14

     FILE 'WPIDS' ENTERED AT 15:04:27 ON 29 OCT 2001
L16           7 S IRIS## AND (L7 OR L8 OR L10 OR L12)
L17           6 S L16 NOT (L14 OR L15)

=> d .wp 1-6

L17  ANSWER 1 OF 6  WPIDS COPYRIGHT 2001   DERWENT INFORMATION LTD
AN   2000-237524 [20]   WPIDS
DNC  C2000-072211
TI   Inhibition of angiogenesis and endothelial cell proliferation in
     angiogenesis-related diseases e.g. macular degeneration and uterine
     vascularization by administering melanin.
DC   B04
IN   D'AMATO, R J
PA   (CHIL-N) CHILDRENS MEDICAL CENT
CYC  88
PI   WO 2000010507 A2 20000302 (200020)* EN   30p
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
            PT SD SE SL SZ UG ZW
         W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
            FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
            LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
            TM TR TT UA UG US UZ VN YU ZA ZW
     AU 9963132    A  20000314 (200031)
     EP 1119252    A2 20010801 (200144)  EN
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
            RO SE SI
ADT  WO 2000010507 A2 WO 1999-US19026 19990820; AU 9963132 A AU 1999-63132
     19990820; EP 1119252 A2 EP 1999-967818 19990820, WO 1999-US19026 19990820
FDT  AU 9963132 A Based on WO 200010507; EP 1119252 A2 Based on WO 200010507
PRAI US 1998-97385    19980821
AB   WO 200010507 A UPAB: 20000426
     NOVELTY - Inhibiting angiogenesis in an individual by administering
     melanin, is new.
          DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
     following:
          (1) inhibiting angiogenesis in an individual by administering a
     melanin-promoting compound; and
          (2) treating macular degeneration in an individual by administering
     melanin or a melanin-promoting compound.
          ACTIVITY - Antiangiogenic; anti-macular degeneration; antidiabetic;
     immunosuppressive; keratolytic; dermatological; antibacterial; vulnerary;
```

antiulcer; cytostatic; anti-HIV; antirheumatic; antiarthritic; antiinflammatory; tranquilizer; vasotropic; **antiarteriosclerotic** ; antipsoriatic; cerebroprotective; gynecological.

Pellets of bovine fibroblast growth factor (bFGF) were placed in corneas of mice pigmented C57b16, substrain C57b16J/Tyr-c albino (mutation in tyrosinase), 129J (normally albino) and pigmented 129/SV+p+Tyr-c. None of the pigmented mice of C57b16 showed **iris** vessel growth and bleeding while the growth was 7/8, 17/18 and 2/17 respectively. The growth % was 0, 88, 94 and 12 respectively.

MECHANISM OF ACTION - In vitro endothelial cell proliferation inhibitor; angiogenesis inhibitor.

USE - To treat angiogenesis-related diseases in both humans and animals e.g. diabetic retinopathy; corneal neovascularization e.g. epidemic keratoconjunctivitis, atopic keratitis; retinal/choroidal neovascularization e.g. macular degeneration, Lyme's disease, toxoplasmosis; rheumatoid arthritis; chronic inflammation e.g. ulcerative colitis, Crohn's disease; atherosclerosis; hemangioma; solid tumor formation;hematopoiesis; ovulation; menstruation and placentation. Also as birth control agent to prevent or reduce uterine vascularization for embryo implantation. Addition of 38 mg melanin to the cornea of albino mice decreases the ability of bFGF pellets to induce angiogenesis by 24% when compared to non-melanin controls.

ADVANTAGE - The composition provides a therapy for macular degeneration that has minimal side effects.

Dwg.0/0

L17 ANSWER 2 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-272116 [24] WPIDS
DNC C1998-084957
TI New aryl-amino compounds mediating the effect of somatostatin agonists or antagonists - useful for treating medical disorders related to binding to human somatostatin receptor subtype(s).
DC B03 B05
IN ANKERSEN, M; CRIDER, A M; DORWALD, F Z; STIDSEN, C E; DOERWALD, F Z; CARSTEN, E S; ZARAGOZA, D F
PA (NOVO) NOVO-NORDISK AS
CYC 80
PI WO 9818786 A1 19980507 (199824)* EN 45p
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW
ZA 9709701 A 19980729 (199835) 40p
AU 9747724 A 19980522 (199840)
EP 937065 A1 19990825 (199939) EN
R: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV NL PT RO SE SI
US 6020349 A 20000201 (200013)
US 6083960 A 20000704 (200036)
JP 2001502712 W 20010227 (200115) 48p
ADT WO 9818786 A1 WO 1997-DK488 19971029; ZA 9709701 A ZA 1997-9701 19971029; AU 9747724 A AU 1997-47724 19971029; EP 937065 A1 EP 1997-910268 19971029, WO 1997-DK488 19971029; US 6020349 A US 1997-962098 19971031; US 6083960 A Div ex US 1997-962098 19971031, US 1999-397355 19990916; JP 2001502712 W WO 1997-DK488 19971029, JP 1998-519947 19971029
FDT AU 9747724 A Based on WO 9818786; EP 937065 A1 Based on WO 9818786; US 6083960 A Div ex US 6020349; JP 2001502712 W Based on WO 9818786
PRAI DK 1996-1216 19961031
AB WO 9818786 A UPAB: 19981021
Compounds of formula (I), and their salts are new. A = aryl optionally substituted with one or more halo, amino, hydroxyl, nitro, 1-6C alkyl, 1-6C alkoxy or aryl; B = aryl optionally substituted with one or more

halo, amino, hydroxyl, 1-6C alkyl, 1-6C alkoxy or aryl; m = 0-6; n = 0-3; Y = valence bond or group of formula (i); q and s = 0-5 and q + s = 1-5; R1 = H or 1-6C alkyl optionally substituted with halo, amino, hydroxy, 1-6C alkoxy or aryl; E = N(R2)-D or group of formula (ii); p = 0-4; r = 1-6; Z = N or CH; D = aryl optionally substituted with one or more halo, amino, hydroxyl, 1-6C alkyl, 1-6C alkoxy, piperidinyl or aryl; R2 = H or 1-6C alkyl optionally substituted with halo, amino, hydroxy, 1-6C alkoxy or aryl; with the proviso that if m = 0 then Y is not a valence bond.

USE - (I) are useful prophylactically or therapeutically for mediating the biological effect of somatostatin agonists or antagonists. Compositions are administered by oral, nasal, buccal, transdermal, pulmonal or parenteral routes. (I) are useful in treatment of airway disorders such as asthma, as anti-diarrhoeals and for the modulation of gastric acid secretion, for treatment of diseases associated with regulation of sleep and wakefulness and for the treatment of narcolepsy and attention deficit disorders, for use as non-amphetamine-like stimulants or as sedatives, for the treatment of eating disorders (e.g. anorexia or bulimia) by virtue of their appetite regulating properties, for treatment of conditions associated with epilepsy, for treatment of motion sickness and vertigo and for the treatment of dementia and Alzheimer disease. (I) are useful for modulation of glucagon and insulin secretion to treat type I and type II diabetes, treatment of CFS, inhibition of cell proliferation and growth to treat various endocrine and exocrine tumours, modulation of growth hormone secretion to treat dwarfism, acromegaly and other growth abnormalities, modulation of immune responses to treat autoimmune diseases, rheumatoid arthritis and other inflammations, modulation of neuronal activity to treat diseases related to the central nervous system, i.e. pain, anxiety, memory disorders, affective disorders and Alzheimer's disease, modulation of intestinal water uptake to treat congestion and diarrhoea, inhibition of arterial smooth muscle cell proliferation to treat restenosis and **arteriosclerosis**, inhibition of airway mucous secretion to treat asthma and mucoviscidosis, modulation of lipid metabolism and regulation of energy balance to treat obesity, inhibition of acid secretion to treat ulcer, inhibition of pancreatic secretions to treat acute pancreatitis, for the treatment of a disease associated with an adverse condition in the retina and/or **iris**/ciliary body of a mammal, such conditions being high intraocular pressure (IOP) and/or deep ocular infections, e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. (I) are useful for development of pharmaceutical, therapeutic and diagnostic techniques.

Dwg.0/0

L17 ANSWER 3 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1995-344451 [44] WPIDS
DNC C1995-151377
TI Treating glaucoma or ocular hypertension - using new or known thio prostaglandin cpds., reducing intraocular pressure without irritation.
DC B05
IN BITO, L Z; RESUL, B; STJERNSCHANTZ, J; STJERNSCHANTZ, J W
PA (PHAA) PHARMACIA AB; (KABI) KABI PHARMACIA AB
CYC 58
PI WO 9525520 A1 19950928 (199544)* EN 27p
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SI SK TJ TT UA UZ VN
AU 9521546 A 19951009 (199603)
US 5516796 A 19960514 (199625) 7p
ADT WO 9525520 A1 WO 1995-SE316 19950324; AU 9521546 A AU 1995-21546 19950324; US 5516796 A US 1994-217515 19940324
FDT AU 9521546 A Based on WO 9525520
PRAI US 1994-217515 19940324
AB WO 9525520 A UPAB: 19951109

A pharmaceutical compsn. contains a thioprostaglandin cpd. of formula (I) in an ophthalmologically acceptable carrier. X = 5-7 membered ring; R1 = (a) opt. branched alkyl or alkene chain; (b) cycloalkyl or cycloalkyl having 6-7 ring C; heteroatom substd. cycloalkyl or cycloalkenyl having 3-7 ring atoms; aryl; or heteroaryl; (c) opt. branched alkyl or alkene chain interrupted by or incorporating one or more heteroatoms selected from O, S and N, or a gp. (a) or (b) which is substd. by or incorporates a ring structure as in (b); or (d) a gp. (c) or (d) (sic) in which the ring structure is further substd. by one or more of 1-5C alkyl, 1-3C aliphatic acylamino, NO2, halo and aryl.

USE - As well as the claimed uses for treating glaucoma and ocular hypertension, (I) may be active on other organ systems (e.g. the gastrointestinal and **cardiovascular** systems). Specifically (Ia) and (Ib) stimulate the rate fundus, cat or bovine **iris** sphincter and the circular (but not longitudinal) prepn. of guinea pig ileum, and affect platelet aggregation.

ADVANTAGE - (I) provide maximal lowering of intraocular pressure (IOP), while causing minimal side-effects such as ocular irritation. Dwg.0/0

L17 ANSWER 4 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1991-222645 [30] WPIDS
DNC C1991-096668
TI Use of inositol phosphate derivs. - for treating tissue damage, diabetes and its complications, disorders related to transplantation, **cardiovascular** diseases, etc..
DC B05
IN SIR, N; SIREN, M
PA (PEST) PERSTORP AB
CYC 17
PI WO 9109601 A 19910711 (199130)*
AU 9169700 A 19910724 (199143)
EP 505452 A1 19920930 (199240) EN 18p
GB 2255505 A 19921111 (199246) 18p
JP 05502864 W 19930520 (199325) 7p
US 5342832 A 19940830 (199434) 4p
EP 505452 B1 19960619 (199629) EN 6p
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE
DE 69027540 E 19960725 (199635)
ES 2090303 T3 19961016 (199647)
ADT EP 505452 A1 WO 1990-SE842 19901218, EP 1991-901333 19901218; GB 2255505 A WO 1990-SE842 19901218, GB 1992-12113 19920608; JP 05502864 W WO 1990-SE842 19901218, JP 1991-501719 19901218; US 5342832 A WO 1990-SE842 19901218, US 1992-862564 19920821; EP 505452 B1 WO 1990-SE842 19901218, EP 1991-901333 19901218; DE 69027540 E DE 1990-627540 19901218, WO 1990-SE842 19901218, EP 1991-901333 19901218; ES 2090303 T3 EP 1991-901333 19901218
FDT EP 505452 A1 Based on WO 9109601; GB 2255505 A Based on WO 9109601; JP 05502864 W Based on WO 9109601; US 5342832 A Based on WO 9109601; EP 505452 B1 Based on WO 9109601; DE 69027540 E Based on EP 505452, Based on WO 9109601; ES 2090303 T3 Based on EP 505452
PRAI SE 1989-4355 19891221
AB WO 9109601 A UPAB: 19930928
Use of inositolphosphate derivs. of formula C6H6(OH)6-n(OPO3H2)n (I) (n = 1 or 2) for preventing, alleviating or combating tissue damage such as oedema formation and vascular linkage, diabetes or its complications such as osteoporosis and bone erosion, disorders related to transplantation such as rejection, abnormal levels of lipoproteins, **cardiovascular** diseases, haemorrhage and inflammatory conditions is claimed.

The use of 16 cpds. is specifically claimed, e.g. myo-inositol-monophosphate and scylloinositol-bis-phosphate. Also claimed is a compsn. comprising (I) and a carrier, excipient or additive. The use is 0.1-1000 (0.1-200) mg/kg/day.

USE/ADVANTAGE - (I) are also used for treating damage to cell

membranes, metal intoxication, conditions of ischaemia and reperfusion, conditions of shock, conditions related to vasculitis, dermatitis, gastrointestinal diseases, synovitis, periodontal and cerebral diseases, autoimmune diseases, eye diseases, light and oxygen induced diseases or damage and skin damage. (I) improves stabilisation, decreases deformation and improves the function of different cells. (I) also regulates membrane fluidity, the incorporation of cell membrane components and the prodn. incorporation and balance between different phospholipids.
0/0

L17 ANSWER 5 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1990-348222 [46] WPIDS
DNN N1990-266074
TI Monitoring device for body functions e.g. during anaesthesia - comprises scleral contact lens with light source and light receiver to illuminate retina.
DC P31 S03 S05
IN GLYNN, C J; HILL, A R
PA (GLYN-I) GLYNN C J; (HILL-I) HILL A R
CYC 17
PI WO 9012534 A 19901101 (199046)* 40p
RW: AT BE CH DE DK ES FR GB IT LU NL SE
W: AU CA GB JP US
AU 9055379 A 19901116 (199107)
EP 471725 A 19920226 (199209)
R: AT BE CH DE ES FR GB IT LI NL SE
GB 2248297 A 19920401 (199214) 1p
JP 04504670 W 19920820 (199240) 11p
GB 2265003 A 19930915 (199337) 36p
GB 2248297 B 19931124 (199347) 2p
GB 2265003 B 19931201 (199348) 2p
US 5297554 A 19940329 (199412) 15p
AU 9453038 A 19940303 (199414)
AU 646804 B 19940310 (199415)
AU 655570 B 19941222 (199507)
EP 686372 A1 19951213 (199603) EN 16p
R: AT CH DE ES FR IT LI NL
EP 471725 B1 19951227 (199605) EN 20p
R: AT BE CH DE DK ES FR GB IT LI NL SE
DE 69024490 E 19960208 (199611)
ES 2084029 T3 19960501 (199625)
CA 2051419 C 20000118 (200024) EN
EP 686372 B1 20010117 (200105) EN
R: AT CH DE ES FR IT LI NL
DE 69033694 E 20010222 (200118)
ES 2156170 T3 20010616 (200141)
ADT EP 471725 A EP 1990-907221 19900426; GB 2248297 A GB 1990-21230 19900426; JP 04504670 W JP 1990-506667 19900426, WO 1990-GB648 19900426; GB 2265003 A Derived from GB 1991-21230 19900426, GB 1993-8630 19930426; GB 2248297 B WO 1990-GB648 19900426, GB 1991-21230 19900426; GB 2265003 B Derived from GB 1991-21230 19900426, GB 1993-8630 19930426; US 5297554 A WO 1990-GB648 19900426, US 1991-768645 19910927; AU 9453038 A AU 1994-53038 19940106, Div ex AU 1990-55379 ; AU 646804 B AU 1990-55379 19900426; AU 655570 B AU 1994-53038 19940106, Div ex AU 1990-55379 ; EP 686372 A1 EP 1995-108792 19900426; EP 471725 B1 EP 1990-907221 19900426, WO 1990-GB648 19900426; DE 69024490 E DE 1990-624490 19900426, EP 1990-907221 19900426, WO 1990-GB648 19900426; ES 2084029 T3 EP 1990-907221 19900426; CA 2051419 C CA 1990-2051419 19900426, WO 1990-GB648 19900426; EP 686372 B1 Div ex EP 1990-907221 19900426, EP 1995-108792 19900426; DE 69033694 E DE 1990-633694 19900426, EP 1995-108792 19900426; ES 2156170 T3 EP 1995-108792 19900426
FDT JP 04504670 W Based on WO 9012534; GB 2248297 B Based on WO 9012534; US 5297554 A Based on WO 9012534; AU 646804 B Previous Publ. AU 9055379,

Based on WO 9012534; AU 655570 B Previous Publ. AU 9453038; EP 471725 B1 Based on WO 9012534; DE 69024490 E Based on EP 471725, Based on WO 9012534; ES 2084029 T3 Based on EP 471725; CA 2051419 C Based on WO 9012534; EP 686372 B1 Div ex EP 471725; DE 69033694 E Based on EP 686372; ES 2156170 T3 Based on EP 686372

PRAI GB 1989-9491 19890426

AB WO 9012534 A UPAB: 19930928

The device comprises a scleral contact lens (1) for locating and supporting at least one discrete light source e.g. an optical fibre (9) or a light emitting diode, and at least one discrete light receiver e.g. an optical fibre (10) or a photodetector, mounted within a carrier (6) on the scleral contact lens. The arrangement is such that, in use, light from the light source is directed through the contact lens towards the eye to illuminate the retina of the eye independently of pupil size.

The light receiver is positioned to receive light returning through the lens directly from that portion of the retina which is illuminated directly by the light input to maximise the quantity of light received.

USE - Non-invasive, real-time monitoring of **cardiovascular**, respitory neuromuscular and other bodily functions.

8/11

L17 ANSWER 6 OF 6 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1980-74836C [42] WPIDS

TI Non-alcoholic tonic drink - contg. sugar, citric and acetic acids, eleuterococcus extract, vanillin, infusions of lemon, tea, tarragon and **iris** root, and water.

DC D13

IN BLIADZE, M V; ERISTAVI, L I; MIKELADZE, G G

PA (TBIL-R) TBILISI MEDICINE INST; (UYTB-R) TBILISI UNIV

CYC 1

PI SU 719595 A 19800310 (198042)*

PRAI SU 1978-2566324 19780109

AB SU 719595 A UPAB: 19930902

Non-alcoholic tonic drink contains (in wt.%): sugar 9.1-9.5, citric acid 0.12-0.16, eleuterococcus extract 0.05-0.15, lemon tea infusion 2.0-2.6, estrogen infusion 0.7-1.2, **iris** root infusion 0.03-0.07, vanilin 0.008-0.018, acetic acid 2.2-2.4; the balance is water. The drink has emerald colour, agreeable taste and aroma.

The combination of caffeine (contained in the lemon-tea infusion) with eleuterosides (present in the eleuterococcus extract) exerts distinct tonic effect. The drink contains vitamin P (catechins of tea and cytrus), C, K, B, B2 and PP, and biologically active ethereal oils. The vitamin P reduces the brittleness of blood vessels, thus preventing **arteriosclerosis**.

```
=> fil medline
FILE 'MEDLINE' ENTERED AT 07:58:24 ON 01 NOV 2001

 FILE LAST UPDATED: 30 OCT 2001 (20011030/UP).  FILE COVERS 1958 TO DATE.

 On April 22, 2001, MEDLINE was reloaded.  See HELP RLOAD for details.

 MEDLINE now contains IN-PROCESS records.  See HELP CONTENT for details.

 MEDLINE is now updated 4 times per week.  A new current-awareness alert
 frequency (EVERYUPDATE) is available.  See HELP UPDATE for more information.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2001 vocabulary.  Enter HELP THESAURUS for details.

 The OLDMEDLINE file segment now contains data from 1958 through 1965.
 Enter HELP CONTENT for details.

 Left, right, and simultaneous left and right truncation are available in the
 Basic Index.  See HELP SFIELDS for details.

 THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE
 SUBSTANCE IDENTIFICATION.

=> d his

     (FILE 'MEDLINE' ENTERED AT 07:44:54 ON 01 NOV 2001)
                DEL HIS Y
L1          77134 S PLANTS, MEDICINAL+NT/CT OR PLANT EXTRACTS+NT/CT
L2             52 S L1 AND (IRIS OR IRISES OR IRIDACE?)
L3             12 S L1 AND TECTORIGENIN?
L4             61 S L2 OR L3
L5              0 S (BELAMCANDA OR BELAMCANDRA) (2W) SINENSIS
L6             11 S BELAMCANDA
L7             65 S L6 OR L4
                  E OSTEOPOROSIS/CT
                  E E3+ALL
                  E ARTERIOSCLEROSIS/CT
                  E E3+ALL
                  E E2+ALL
                  E CLIMACTERIC/CT
                  E E3+ALL
L8              0 S L7 AND (C14./CT OR OSTEOPOROSIS+NT/CT OR HEART DISEASE+NT/CT)
L9              0 S L7 AND (C14./CT OR OSTEOPOROSIS+NT/CT OR CLIMACTERIC+NT/CT)
L10             0 S L7 AND ESTROGEN?

     FILE 'MEDLINE' ENTERED AT 07:58:24 ON 01 NOV 2001
```

```
=> fil biosis
FILE 'BIOSIS' ENTERED AT 08:05:04 ON 01 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 31 October 2001 (20011031/ED)

The BIOSIS file has been reloaded.  Enter HELP RLOAD and HELP REINDEXING
for details.

=> d his

     (FILE 'MEDLINE' ENTERED AT 07:58:24 ON 01 NOV 2001)
               DEL HIS Y

     FILE 'BIOSIS' ENTERED AT 07:58:54 ON 01 NOV 2001
L1          3741 S IRIDACEAE? OR IRIS (4A) (PLANT# OR EXTRAC?)
L2            49 S TECTORIGENIN?
L3            53 S BELAMCANDA OR BELAMCANDRA
L4          3777 S L1 OR L2 OR L3
L5        302539 S EXTRACT? OR EXT#
L6           243 S L4 AND L5
L7         54153 S ARTERIOSCLE? OR ATHEROSCLER?
L8             1 S L6 AND L7
L9        166804 S (CARDIOVASCULAR OR HEART?) (4A) DISEASE?
L10            0 S L9 AND L6
L11        24692 S OSTEOPOROSIS? OR MENOPAUSE OR CLIMACTERIC
L12            0 S L6 AND L11
L13            2 S L4 AND L7
L14            0 S L4 AND L9
L15            3 S L4 AND L11
L16            5 S L8 OR L13 OR L15

     FILE 'BIOSIS' ENTERED AT 08:05:04 ON 01 NOV 2001

=> d bib ab it 1-5

L16  ANSWER 1 OF 5  BIOSIS  COPYRIGHT 2001 BIOSIS
AN   1995:484679  BIOSIS
DN   PREV199598498979
TI   Senescence and ethylene production of cut gladiolus.
AU   Hwang, Moon Joo; Kwon, Hye Jin; Kim, Ki Sun; Lee, Seung Koo
CS   Dep. Horticulture, Seoul National University, Suwon 441-744 South Korea
SO   Journal of the Korean Society for Horticultural Science, (1995) Vol. 36,
     No. 4, pp. 555-559.
     ISSN: 0253-6498.
DT   Article
LA   Korean
SL   Korean; English
AB   This study was conducted 1) to investigate the postharvest physiology and
     2) to examine the effect of ethylene on postharvest senescence of
     gladiolus (Gladiolus gandavensis cv. Spic and Span). Ethylene production
     and respiration rate of each spike was monitored daily. Ethylene
     production was peaked at 6 days after harvest. Gladiolus spikes were
     placed in ethephon solution, ranging 100, 200 and 400 ppm. Typical
     climacteric pattern of ethylene production, promoted senescence by
     ethephon application, and extended vase life by STS treatment, an
     inhibitor of ethylene action, suggested that ethylene may be involved in
     senescence of cut gladiolus.
```

IT Major Concepts
Bioenergetics (Biochemistry and Molecular Biophysics); Chemical Coordination and Homeostasis; Development; Horticulture (Agriculture)
IT Chemicals & Biochemicals
ETHYLENE; SILVER THIOSULFATE
IT Miscellaneous Descriptors
CLIMACTERIC; PLANT GROWTH REGULATOR; RESPIRATION; SILVER THIOSULFATE; VASE LIFE
ORGN Super Taxa
Iridaceae: Monocotyledones, Angiospermae, Spermatophyta, Plantae
ORGN Organism Name
Gladiolus gandavensis (**Iridaceae**)
ORGN Organism Superterms
angiosperms; monocots; plants; spermatophytes; vascular plants
RN 74-85-1 (ETHYLENE)
23149-52-2 (SILVER THIOSULFATE)

L16 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1995:377630 BIOSIS
DN PREV199598391930
TI Evaluation of non-**climacteric** senescence of Gladiolus sp. flowers.
AU Pemberton, G. H.; Nell, Terril A.; Barrett, James E.
CS Dep. Environ. Horticulture, Univ. Fla., Gainesville, FL 32611 USA
SO Hortscience, (1995) Vol. 30, No. 4, pp. 760.
Meeting Info.: 92nd Annual Meeting of the American Society for Horticultural Science and the 40th Annual Congress of the Canadian Society for Horticultural Science Montreal, Quebec, Canada July 30-August 3, 1995
ISSN: 0018-5345.
DT Conference
LA English
IT Major Concepts
Bioenergetics (Biochemistry and Molecular Biophysics); Chemical Coordination and Homeostasis; Development; Horticulture (Agriculture); Metabolism
IT Chemicals & Biochemicals
ETHYLENE
IT Industry
crop industry
IT Miscellaneous Descriptors
ETHYLENE PRODUCTION; HORTICULTURE; MEETING ABSTRACT; POSTHARVEST LIFE; PROTEIN CONTENT; RESPIRATION
ORGN Super Taxa
Iridaceae: Monocotyledones, Angiospermae, Spermatophyta, Plantae; Plantae - Unspecified: Plantae
ORGN Organism Name
plant (Plantae - Unspecified); Gladiolus (**Iridaceae**)
ORGN Organism Superterms
angiosperms; monocots; plants; spermatophytes; vascular plants
RN 74-85-1 (ETHYLENE)

L16 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1994:436271 BIOSIS
DN PREV199497449271
TI Role of ethylene in opening and senescence of Gladiolus sp. flowers.
AU Serek, Margrethe (1); Jones, Rodney B.; Reid, Michael S.
CS (1) Royal Vet. Agric. Univ., Dep. Agric. Sci., Section Horticulture, Rolighedsvej 23, 1958 Frederiksberg C Denmark
SO Journal of the American Society for Horticultural Science, (1994) Vol. 119, No. 5, pp. 1014-1019.
ISSN: 0003-1062.
DT Article

LA English
AB The opening and senescence of gladiolus (Gladiolus sp.) florets was accompanied by **climacteric** or nonclimacteric patterns of respiration and ethylene production, depending on variety, and whether data were expressed on a fresh-weight or floret basis. A **climacteric** pattern of ethylene production by the youngest buds on the spike (which never opened) was stimulated by cool storage, and was not affected by holding the spikes in a preservative solution containing sucrose. Ethylene treatment had no effect on senescence of the florets of any of the cultivars tested. Pulse treatment of the spikes with silver thiosulfate (STS) improved floret opening but not the life of individual florets. Sucrose and STS had similar but not synergistic effects on floret opening, suggesting that STS improves flower opening in gladiolus by overcoming the effects of carbohydrate depletion.
IT Major Concepts
Biochemistry and Molecular Biophysics; Bioenergetics (Biochemistry and Molecular Biophysics); Chemical Coordination and Homeostasis; Horticulture (Agriculture); Metabolism; Reproduction
IT Chemicals & Biochemicals
ETHYLENE; SUCROSE; SILVER THIOSULFATE
IT Miscellaneous Descriptors
CARBOHYDRATE; HORTICULTURE; RESPIRATION; SILVER THIOSULFATE; SUCROSE
ORGN Super Taxa
Iridaceae: Monocotyledones, Angiospermae, Spermatophyta, Plantae; Plantae - Unspecified: Plantae
ORGN Organism Name
plant (Plantae - Unspecified); Gladiolus sp. (**Iridaceae**)
ORGN Organism Superterms
angiosperms; monocots; plants; spermatophytes; vascular plants
RN 74-85-1 (ETHYLENE)
57-50-1 (SUCROSE)
23149-52-2 (SILVER THIOSULFATE)

L16 ANSWER 4 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1981:164819 BIOSIS
DN BA71:34811
TI HISTO PATHOLOGICAL CHANGES AFTER PSEUDOPHAKOS.
AU SUTTON G A; BARRY D R
CS BIRMINGHAM AND MIDLAND EYE HOSPITAL, CHURCH STREET, BIRMINGHAM B3 2NS ENGLAND .
SO OPHTHALMOLOGICA, (1980) 180 (4), 228-233.
CODEN: OPHTAD. ISSN: 0030-3755.
FS BA; OLD
LA English
AB Cataract **extraction** and **iris** clip lens implantation in an 88 yr old woman were followed by hyphema, anterior uveitis and organized exudates around the implant. The globe was enucleated after 15 mo. due to pain and poor visual prognosis. Sections showed an epithelial downgrowth into part of the anterior chamber, associated with a fibrous membrane which had surrounded part of 1 loop of the implant. Atrophy of the iris, adenomatous changes in a ciliary process and an after-cataractous ring were noted. Inflammatory changes were present in the uvea, associated posteriorly with degenerative choroido-retinitis, probably of **arteriosclerotic** origin. The nylon loops of the implant showed areas of biodegradation and were partly fibrosed in. The possible relationship of the various changes is discussed.
IT Miscellaneous Descriptors
HUMAN HYPHEMA ANTERIOR UVEITIS IRIS ATROPHY DEGENERATIVE CHOROIDO RETINITIS IRIS CLIP LENS IMPLANTATION COMPLICATION INFLAMMATION EPITHELIAL DOWNGROWTH CATARACT **EXTRACTION**

L16 ANSWER 5 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1979:178754 BIOSIS

DN BA67:58754
TI COMPOUNDS THAT INCREASE OXYGEN DIFFUSION IN PLASMA.
AU KURYEL R; AKGERMAN A
CS CHEM. ENG. DEP., EGE UNIV., BORNOVA, IZMIR, TURK.
SO ATHEROSCLEROSIS, (1978) 29 (2), 131-140.
CODEN: ATHSBL. ISSN: 0021-9150.
FS BA; OLD
LA English
AB The rate of diffusion of O2 in [human] blood plasma is increased by adding certain compounds [procaine, clofibrate, vitamin A, crocetin] to plasma at very low concentration levels. Decreased O2 diffusion rates in plasma causes local hypoxic conditions and this may be important in the pathogenesis of **atherosclerosis**.
IT Miscellaneous Descriptors
HUMAN ATHERO SCLEROSIS PROCAINE CLOFIBRATE CROCETIN VITAMIN A HYPOXIA
RN 59-46-1 (PROCAINE)
637-07-0 (CLOFIBRATE)
7782-44-7 (OXYGEN)
27876-94-4 (CROCETIN)
68-26-8Q, 11103-57-4Q (VITAMIN A)